# Toll-like receptor agonist payloads

Source: https://onco.cc/terms/tlr-agonist-payloads/  
OnCo record `tlr-agonist-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads stimulate immune-cell sensors that recognize danger. The goal is to direct immune activation toward a tumor using an antibody.

## Summary

TLR7/8 agonist antibody conjugates have induced myeloid activation and adaptive immune responses in preclinical studies. The Ackerman study required tumor-antigen recognition, Fc-receptor-dependent phagocytosis and TLR activation, rather than payload toxicity alone. BDC-1001 and SBT6050 are human-study examples. The BDC-1001 registry studies are terminated; one SBT6050 study is of unknown status and another is terminated. Unknown status should not be presented as recruiting.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: TLR7/8 agonist payloads; TLR8 agonist conjugates; TLR7 agonist conjugates

## Sources

- Ackerman et al., immune-stimulating conjugates (2021): https://doi.org/10.1038/s43018-020-00136-x
- ClinicalTrials.gov: NCT04278144: https://clinicaltrials.gov/study/NCT04278144
- ClinicalTrials.gov: NCT05954143: https://clinicaltrials.gov/study/NCT05954143
- ClinicalTrials.gov: NCT04460456: https://clinicaltrials.gov/study/NCT04460456
- ClinicalTrials.gov: NCT05091528: https://clinicaltrials.gov/study/NCT05091528

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune-stimulating antibody conjugate (ISAC)](https://onco.cc/technologies/immune-stimulating-adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)

---
JSON: https://onco.cc/api/v1/entities/tlr-agonist-payloads.json